2-(4-nitro-phenoxy)-butyric acid | 120552-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-nitro-phenoxy)-butyric acid
• 英文别名: α-(4-Nitro-phenoxy)-buttersaeure；2-(4-Nitro-phenoxy)-buttersaeure；2-(4-Nitrophenoxy)butanoic acid
• CAS: 120552-01-4
• 化学式: C₁₀H₁₁NO₅
• mdl: MFCD03422253
• 分子量: 225.201
• InChiKey: YPBRRZJQNAFLIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-(4-nitro-phenoxy)-butyric acid 在 氯化亚砜 、 铁粉 、 potassium carbonate 、 氯化铵 、 三氟乙酸 、 potassium iodide 作用下， 以 甲醇 、 水 、 乙腈 、 仲丁醇 为溶剂， 反应 19.0h， 生成 2-[[5-chloro-2-[4-[2-(4-(1-oxygen-4-phenylamino))ethyl-3-formyl]-morpholine]pyrimidin-4-yl]amino]-N-methylbenzamide
  参考文献：
  名称：

  Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells

  摘要：

  A family of carbonyl substituted diphenylpyrimidine derivatives (Car-DPPYs) with strong activity against focal adhesion kinase (FAK), were described in this manuscript. Among them, compounds 7a (IC50 = 5.17 nM) and 7f (IC50 = 2.58 nM) displayed equal anti-FAK enzymatic activity to the lead compound TAE226 (6.79 nM). In particular, compound 7a also exhibited strong antiproliferative activity against several stubborn cancer cells, including AsPC-1 cells (IC50 = 0.105 mu M), BxPC-3 cells (IC50 = 0.090 mu M), and MCF-7/ADR cells (IC50 = 0.59 mu M). Additionally, compound 7a also showed great antitumor efficacy in vivo via aAsPC-1 cancer Xenograft mouse model. The preliminary mechanism study by Western blot analysis revealed that 7a repressed FAK phosphorylation in AsPC cancer cells. Taken together, the results indicate that compound 7a may serve as a promising preclinical candidate for treatment of stubborn cancers. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.04.004
• 作为产物：
  描述：

  4-nitrophenol sodium salt 生成 2-(4-nitro-phenoxy)-butyric acid
  参考文献：
  名称：

  Bischoff, Chemische Berichte, 1900, vol. 33, p. 1605

  摘要：

  DOI：

文献信息

• Aminophenylpropanoic Acid Derivative
  申请人：Yasuma Tsuneo

  公开号：US20080269220A1

  公开（公告）日：2008-10-30

  A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.

  化合物的化学式为（1）：其中每个符号如规范所定义，其盐和前药意外地具有更优越的GPR40受体激动剂活性，在药品产品的稳定性等方面具有优越性，并且可以作为安全有效的药物用于预防或治疗GPR40受体相关的病理或疾病，例如糖尿病等。
• 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2316459B1

  公开（公告）日：2013-11-06
• US7786165B2
  申请人：——

  公开号：US7786165B2

  公开（公告）日：2010-08-31
• Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells
  作者：Luhong Wang、Min Ai、Jiawen Yu、Lingling Jin、Changyuan Wang、Zhihao Liu、Xiaohong Shu、Zeyao Tang、Kexin Liu、Hui Luo、Wenshun Guan、Xiuli Sun、Xiaodong Ma

  DOI：10.1016/j.ejmech.2019.04.004

  日期：2019.6

  A family of carbonyl substituted diphenylpyrimidine derivatives (Car-DPPYs) with strong activity against focal adhesion kinase (FAK), were described in this manuscript. Among them, compounds 7a (IC50 = 5.17 nM) and 7f (IC50 = 2.58 nM) displayed equal anti-FAK enzymatic activity to the lead compound TAE226 (6.79 nM). In particular, compound 7a also exhibited strong antiproliferative activity against several stubborn cancer cells, including AsPC-1 cells (IC50 = 0.105 mu M), BxPC-3 cells (IC50 = 0.090 mu M), and MCF-7/ADR cells (IC50 = 0.59 mu M). Additionally, compound 7a also showed great antitumor efficacy in vivo via aAsPC-1 cancer Xenograft mouse model. The preliminary mechanism study by Western blot analysis revealed that 7a repressed FAK phosphorylation in AsPC cancer cells. Taken together, the results indicate that compound 7a may serve as a promising preclinical candidate for treatment of stubborn cancers. (C) 2019 Elsevier Masson SAS. All rights reserved.
• Bischoff, Chemische Berichte, 1900, vol. 33, p. 1605
  作者：Bischoff

  DOI：——

  日期：——